share_log

百利天恒(688506.SH):注射用BL-B01D1用于治疗局部晚期或转移性鼻咽癌末线患者纳入突破性治疗品种名单

Baili Tianheng (688506.SH): Injectable BL-B01D1 is used to treat terminal patients with locally advanced or metastatic nasopharyngeal cancer included in the list of breakthrough treatment varieties

Zhitong Finance ·  Apr 17 03:55

Baili Tianheng (688506.SH) announced that the company's self-developed innovative biopharmaceutical injectable BL-B01D1...

Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical injectable BL-B01D1 (EGFR × HER3-ADC) independently developed by the company to treat advanced locally or metastatic nasopharyngeal cancer patients has been included in the list of breakthrough treatment types by the Drug Evaluation Center of the State Drug Administration (hereinafter referred to as the “Drug Review Center”), which has recently been announced.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment